Relay Therapeutics, Inc. (RLAY)

Market Cap	1.55B +88.9%
Revenue (ttm)	8.36M -16.5%
Net Income	-297.59M
EPS	-1.75
Shares Out	173.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,455,673
Open	8.38
Previous Close	8.15
Day's Range	8.33 - 9.01
52-Week Range	1.78 - 9.04
Beta	1.62
Analysts	Strong Buy
Price Target	15.75 (+76.57%)
Earnings Date	Feb 25, 2026

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 16, 2020
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: RLAY
• Website: https://www.relaytx.com

Financial Performance

In 2024, Relay Therapeutics's revenue was $10.01 million, a decrease of -60.83% compared to the previous year's $25.55 million. Losses were -$337.71 million, -1.25% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $15.75, which is an increase of 76.57% from the latest price.

Price Target

$15.75

(76.57% upside)

Analyst Consensus: Strong Buy